​

Ventyx Biosciences (VTYX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

VTYX Stock Forecast

Ventyx Biosciences (VTYX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $33.86, with a high of $60.00 and a low of $6.00. This represents a 2545.31% increase from the last price of $1.28.

- $12 $24 $36 $48 $60 High: $60 Avg: $33.86 Low: $6 Last Closed Price: $1.28

VTYX Stock Rating

Ventyx Biosciences stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

VTYX Price Target Upside V Benchmarks

TypeNameUpside
StockVentyx Biosciences2545.31%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$8.00
Last Closing Price$1.28$1.28$1.28
Upside/Downside--525.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25153--9
Mar, 25153--9
Feb, 25153--9
Jan, 25153--9
Dec, 24153--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 13, 2024Emily BodnarH.C. Wainwright$6.00$2.98101.34%368.75%
Jun 06, 2024Jeff JonesOppenheimer$10.00$5.2889.39%681.25%
Mar 12, 2024Derek ArchilaWells Fargo$16.00$8.4290.02%1150.00%
Mar 12, 2024Jeff JonesOppenheimer$12.00$8.4242.52%837.50%
Dec 19, 2022Goldman Sachs$50.00$32.6453.19%3806.25%
Nov 17, 2022Matthew HarrisonMorgan Stanley$45.00$25.4376.96%3415.63%
Sep 13, 2022Michael YeeJefferies$60.00$38.1157.44%4587.50%
May 12, 2022Yasmeen RahimiPiper Sandler$50.00$14.53244.12%3806.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2025H.C. WainwrightNeutralNeutralhold
Oct 16, 2024H.C. WainwrightNeutralNeutralhold
Sep 24, 2024H.C. WainwrightNeutralNeutralhold
Jun 13, 2024H.C. WainwrightNeutralNeutralhold
Jun 06, 2024Piper SandlerOverweightOverweighthold
Jun 06, 2024OppenheimerOutperformOutperformhold
Mar 12, 2024Wells FargoOverweightupgrade
Dec 19, 2022Goldman SachsBuyinitialise
Sep 13, 2022NeedhamBuyBuyhold
Sep 12, 2022OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.30$-1.97----
Avg Forecast$-3.37$-2.10$-2.06$-1.77$-1.16$-0.33
High Forecast$-2.77$-2.01$-1.29$-1.09$3.04$-0.33
Low Forecast$-3.77$-2.19$-3.35$-2.26$-3.93$-0.33
Surprise %-2.08%-6.19%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$15.28M$124.12M$260.19M
High Forecast---$15.28M$124.12M$260.19M
Low Forecast---$15.28M$124.12M$260.19M
Surprise %------

Net Income Forecast

$-250M $-160M $-70M $20M $110M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-192.96M$-135.12M----
Avg Forecast$-192.96M$-122.72M$-174.73M$-98.22M$-166.72M$-19.36M
High Forecast$-162.43M$-117.44M$-75.44M$-63.97M$178.13M$-19.36M
Low Forecast$-220.44M$-128.01M$-196.02M$-132.47M$-229.80M$-19.36M
Surprise %-10.11%----

VTYX Forecast FAQ

Is Ventyx Biosciences stock a buy?

Ventyx Biosciences stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ventyx Biosciences is a favorable investment for most analysts.

What is Ventyx Biosciences's price target?

Ventyx Biosciences's price target, set by 9 Wall Street analysts, averages $33.86 over the next 12 months. The price target range spans from $6 at the low end to $60 at the high end, suggesting a potential 2545.31% change from the previous closing price of $1.28.

How does Ventyx Biosciences stock forecast compare to its benchmarks?

Ventyx Biosciences's stock forecast shows a 2545.31% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Ventyx Biosciences over the past three months?

  • April 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Ventyx Biosciences’s EPS forecast?

Ventyx Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.06, marking a 4.57% increase from the reported $-1.97 in 2024. Estimates for the following years are $-1.77 in 2026, $-1.16 in 2027, and $-0.33 in 2028.

What is Ventyx Biosciences’s revenue forecast?

Ventyx Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $15.28M, followed by $124.12M for 2027, and $260.19M for 2028.

What is Ventyx Biosciences’s net income forecast?

Ventyx Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-175M, representing an 29.31% increase from the reported $-135M in 2024. Projections indicate $-98.217M in 2026, $-167M in 2027, and $-19.357M in 2028.